# Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors

> **NCT00074321** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 84 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** irinotecan hydrochloride
- **DRUG:** oxaliplatin
- **DRUG:** capecitabine
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00074321
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2010-07
- **Final completion:** —
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2013-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00074321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00074321, "Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT00074321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*